StudyKIK is at an extremely exciting stage of growth due to the adoption of our expanded services in patient recruitment and digital clinical trial technologies.
IRVINE, Calif. (PRWEB) May 10, 2021
StudyKIK, a global clinical patient recruitment and retention technology company, announces the hiring of Kevin Vass as Chief Financial Officer. This announcement is made as StudyKIK continues to expand its services and technology offerings into new areas. Vass comes to StudyKIK with a great deal of experience in the pharmaceutical industry after spending more than 12 years in a leadership finance position at Amgen and, more recently, at technology company Harman.
Matt Miller, CEO at StudyKIK stated,
“I am pleased to have Kevin join StudyKIK as the company is at an extremely exciting stage of growth due to the adoption of our expanded services in patient recruitment and digital clinical trial technologies. These services will help to better support patients as they enter and participate through a clinical trial and Kevin’s experience will help support StudyKIK through our next stage of growth.”
Kevin Vass, StudyKIK’s recently appointed Chief Financial Officer stated,
“I am looking forward to supporting StudyKKIK through its high growth phase. It’s an exciting time to be a part of this innovative company who is offering a truly novel solution to the clinical trial industry.”
StudyKIK has supported thousands of protocols over the past 7 years and has compiled industry-leading experience in a wide variety of therapeutic areas. Now, coupled with technology solutions in eConsent, Telemedicine, and Study Companion applications for eCOA and ePRO, StudyKIK is the only company connecting the recruitment process with digital technology to simplify clinical trials and provide access to these services under a single platform.
More about StudyKIK:
StudyKIK is a full service patient recruitment and retention technology company that offers Patient Recruitment, Patient Retention, eConsent, Telemedicine, and Study Companion Mobile Apps to ensure study timelines are met. Since its inception, StudyKIK has reached over 6 million patients and connected over 3.5 million patients to studies. As a result, StudyKIK is the global leader in patient recruitment and retention strategy and implementation.